Sonsoles Olivares

50 - EFECTIVIDAD Y SEGURIDAD A CORTO PLAZO DE MIRIKIZUMAB EN COLITIS ULCEROSA: EVIDENCIA EN VIDA REAL DEL REGISTRO ENEIDA DE GETECCU. ESTUDIO MIRICURE

Ana Gutiérrez Casbas, Manuel Barreiro-de Acosta, Luisa de Castro Parga, Lucía Madero-Velázquez et autres

Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

Rocío Ferreiro‐Iglesias, Sol Porto Silva, Sandra Soro Marín, María José Casanova et autres

BACKGROUND: Ulcerative proctitis (UP) can have a milder, less aggressive course than left-sided colitis or extensive colitis. Therefore, immunosuppressants tend to be used less in patients with this condition. Evidence, however, is scarce because these patients are excluded from randomised controlled clinical …

es (code pays fourni par la source)

Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

Fernando Gomollón, Marisa Iborra, Milagros Vela, Agnès Fernández-Clotet et autres

es (code pays fourni par la source)

67 - PSORIASIS INDUCIDA POR TERAPIA ANTI-TNF EN ENFERMEDAD INFLAMATORIA INTESTINAL: ANÁLISIS DEL MANEJO TERAPÉUTICO Y EVOLUCIÓN DE AMBAS ENFERMEDADES EN UN ESTUDIO DE COHORTES A NIVEL NACIONAL

Patricia Sanz Segura, Fernando Gomollón, Víctor Argumánez, Milagros Vela et autres

52 - PRESENTACIÓN CLÍNICA, MANEJO Y EVOLUCIÓN DE LOS LINFOMAS EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL: ESTUDIO NACIONAL BASADO EN EL REGISTRO ENEIDA

Iván Guerra, Luís Bujanda, Míriam Mañosa, Isabel Pérez‐Martínez et autres

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

Iván Guerra, Luís Bujanda, Míriam Mañosa, Isabel Pérez‐Martínez et autres

An increased risk of lymphoma has been described in patients with inflammatory bowel disease (IBD). The aims of our study were to determine the clinical presentation, the previous exposure to immunosuppressive and biologic therapies, and the evolution of lymphomas in patients with …

es (code pays fourni par la source)

Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

Yamile Zabana, Ignacio Marín‐Jiménez, Iago Rodríguez–Lago, Isabel Vera et autres

(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This …

es (code pays fourni par la source)

Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis

Carlos Taxonera, María Jesús Fernández‐Aceñero, David Olivares, Marta Calvo et autres

BACKGROUND: Optimal golimumab concentration thresholds for important outcomes during maintenance are lacking. AIMS: To investigate the association of golimumab trough concentrations during maintenance with key outcomes, including endoscopic and histologic remission, and long-term event-free persistence with golimumab, in patients with UC. METHODS: …

es (code pays fourni par la source)

Mo1534: ASSOCIATION OF GOLIMUMAB TROUGH CONCENTRATIONS DURING MAINTENANCE WITH ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS.

Carlos Taxonera, María Jesús Fernández‐Aceñero, David Olivares, Marta Calvo et autres

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

Yamile Zabana, Ignacio Marín‐Jiménez, Iago Rodríguez–Lago, Isabel Vera et autres

We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the …

es (code pays fourni par la source)